Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
出版年份 2021 全文链接
标题
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
作者
关键词
-
出版物
Cancer Cell International
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-04-07
DOI
10.1186/s12935-021-01891-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
- (2020) Keenan T. Hartert et al. LEUKEMIA
- Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)
- (2020) Xin Xu et al. Cell Death & Disease
- Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation
- (2020) Andrés J. M. Ferreri et al. HEMATOLOGICAL ONCOLOGY
- Micheliolide Protects Against Doxorubicin-Induced Cardiotoxicity in Mice by Regulating PI3K/Akt/NF-kB Signaling Pathway
- (2019) Ashkan Kalantary-Charvadeh et al. Cardiovascular Toxicology
- A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
- (2019) Toby A. Eyre et al. HEMATOLOGICAL ONCOLOGY
- R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial
- (2019) Andrea Kühnl et al. ANNALS OF HEMATOLOGY
- Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
- (2019) Sung-Won Kim et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies
- (2019) Pallawi Torka et al. Current Hematologic Malignancy Reports
- Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma
- (2019) Jennifer L. Crombie et al. Surgical Oncology Clinics of North America
- Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma
- (2018) Thomas D. Rodgers et al. EXPERT OPINION ON EMERGING DRUGS
- Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib
- (2018) Marina Danilenko et al. JAMA Dermatology
- Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk
- (2018) Richard Caldwell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
- (2018) Yaya Chu et al. OncoImmunology
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Clinical approach to diffuse large B cell lymphoma
- (2016) Paolo F. Caimi et al. BLOOD REVIEWS
- Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
- (2016) Grzegorz S. Nowakowski et al. JNCI-Journal of the National Cancer Institute
- Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia
- (2016) L M Saleh et al. LEUKEMIA
- Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease
- (2016) H van Andel et al. ONCOGENE
- CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN
- (2016) Diana Legarda et al. Cell Reports
- Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
- (2016) Grzegorz S. Nowakowski et al. JNCI-Journal of the National Cancer Institute
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia
- (2015) Mansi Arora et al. BLOOD CELLS MOLECULES AND DISEASES
- Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B-cell leukemia
- (2015) Mansi Arora et al. PEDIATRIC BLOOD & CANCER
- Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies
- (2015) BING XIA et al. Oncology Letters
- Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
- (2015) Scott A. Ezell et al. Oncotarget
- Clinical significance of CYLD downregulation in breast cancer
- (2014) Mitsuhiro Hayashi et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
- (2014) Maike Buchner et al. CURRENT OPINION IN HEMATOLOGY
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Novel therapeutic targets in diffuse large B-cell lymphoma
- (2013) Georg Lenz EJC SUPPLEMENTS
- Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance
- (2013) Steve A Maxwell et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia
- (2013) Wei Wu et al. LEUKEMIA & LYMPHOMA
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- (2012) Joseph J. Buggy et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- CYLD Inhibits Tumorigenesis and Metastasis by Blocking JNK/AP1 Signaling at Multiple Levels
- (2011) P. M. de Marval et al. Cancer Prevention Research
- Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I
- (2011) H. Oshiumi et al. JOURNAL OF BIOCHEMISTRY
- Chronicles of a death foretold: Dual sequential cell death checkpoints in TNF signaling
- (2010) Marie Anne O’Donnell et al. CELL CYCLE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ubiquitin chain cleavage: CYLD at work
- (2010) Ramin Massoumi TRENDS IN BIOCHEMICAL SCIENCES
- Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF- B
- (2008) L. Yu et al. BLOOD
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
- (2008) M. S. Czuczman et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now